首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 140 毫秒
1.
早期谷氨酰胺强化肠外营养对危重患者保护机制的研究   总被引:2,自引:0,他引:2  
目的 探讨早期给予谷氨酰胺(Gln)强化肠外营养对危重患者脏器功能的影响及其与预后的关系,进一步探讨谷氨酰胺对危重患者保护的内在机制.方法 选择本院急诊ICU及脑外科收治的44例危重患者,按随机原则分为常规组和Gln强化组,每组22例.两组患者均行肠内、外营养, Gln强化组另予静脉注射Gln 0.4 g·kg-1·d-1,连续7 d.观察两组患者治疗前后体内热休克蛋白70(HSP70)、Gln水平、机械通气时间、细胞免疫功能状况.结果 治疗前常规组和强化组Gln、HSP70水平比较差异无统计学意义(P均>0.05).治疗后常规组Gln、HSP70水平较治疗前稍有增加,但差异无统计学意义;而强化组治疗后Gln、HSP70水平均较治疗前显著升高(P均<0.01),且两组治疗后Gln、HSP70水平比较差异均有统计学意义(P均<0.01).强化组体内Gln与HSP70存在正相关性(r=0.65,P=0.001).两组机械通气时间比较差异有统计学意义(P均<0.05).治疗后强化组CD3、 CD4、CD4/CD8与常规组比较差异有统计学意义(P<0.05).结论 危重患者早期肠外补充Gln能有效改善患者的预后,其机制可能与提高患者体内HSP70水平有关.  相似文献   

2.
崔莹  吴春雪  杨龙  贾春梅  闫寒  李勇  李春学 《临床荟萃》2012,27(4):298-300,303
目的 观察丙氨酰谷氨酰胺(Ala-Gln)对急性肺损伤(ALI)患者的保护作用及其机制.方法 110例ALI患者随机分为对照组(50例)和Ala-Gln组(60例).对照组给予常规治疗,Ala-Gln组在常规治疗的基础上,加用Ala-Gln,疗程7天,分别观察两组间治疗前后血清谷氨酰胺(Gln)、热休克蛋白70(HSP70)水平、急性生理学与慢性健康状况评分Ⅱ(APACHEⅡ)及机械通气时间的差异.结果 Ala-Gln组治疗后血清HSP70、Gln水平明显增高,与治疗前比较差异有统计学意义,HSP70 (1.99±0.66) μg/L vs (1.34±0.68) μg/L( P<0.01);Gln (386.15±68.60)μg/L vs (304.72±73.70) μg/L(P<0.01).与对照组治疗后比较差异亦有统计学意义,Gln (386.15±68.60) μg/L vs (303.74±78.08) μg/L( P<0.01);HSP70 (1.99±0.66) μg/L vs(1.35±0.48)μg/L(P<0.01).Ala-Gln组治疗前后Gln浓度比与HSP70浓度比呈明显正相关(r=0.809,P<0.01),对照组治疗前后血清Gln、HSP70水平差异无统计学意义,对照组治疗前后Gln浓度比与HSP70浓度比无明显相关性(r=0.147,P>0.05).Ala-Gln组机械通气时间明显低于对照组,(162.20±96.33)小时vs (235.00±107.90)小时(P<0.05).治疗后APACHEⅡ评分的改善明显优于对照组,(8.40±2.17)分vs (11.10±2.42)分(P<0.05).结论 Ala-Gln治疗可显著提高ALI患者血清Gln、HSP70水平、缩短机械通气时间,改善APACHEⅡ评分,提示Ala-Gln对ALI患者具有保护作用,其机制可能与提高患者体内Gln、HSP70水平有关.  相似文献   

3.
危重病患者因外科大手术、严重复合创伤、严重感染等应激因素导致体内谷氨酰胺(Glutamine,Cln)消耗急剧增加[1].研究表明危重病患者血Gln水平明显下降,显著低于健康人空腹血浓度(500~700 μmol/L)[2-3].而危重病患者由于各种应激因素导致胃肠功能紊乱甚至衰竭,早期无法通过胃肠道途径补充Gln.本研究旨在评估危重病患者早期肠外补充Gln对体内热休克蛋白70(heat shock proteins70,HSP70)、白介素-6(interleukin-6,IL-6)、D-乳酸水平的影响,以进一步探讨Gln对危重病患者的保护作用及机制.  相似文献   

4.
肌钙蛋白Ⅰ在非心源性危重病患者诊治中的作用研究   总被引:1,自引:0,他引:1  
目的 研究肌钙蛋白I(cTnI)监测在非心源性危重病患者诊治中的作用.方法 选取急诊重症监护室(EICU)收治的非心源性危重病患者215例,按照cTnI的水平分为cTnI升高组(92例)和cTnI正常组(123例).观察两组患者肌酸激酶同工酶(CK-MB)、左室射血分数(LVEF)、APACHEⅡ评分、多器官功能障碍综合征(MODS)发生率、机械通气使用率、ICU入住时间、总住院时间、住院费用、住院病死率和6个月随访期间死亡率. 结果 两组患者CK-MB、LVEF、总住院时间及6个月随访期间死亡率比较差异均无统计学意义(均P>0.05), cTnI升高组APACHEⅡ评分、MODS发生率、机械通气使用率、ICU入住时间、住院费用及住院病死率均高于cTnI正常组(P<0.05,P<0.01).结论 伴有cTnI升高的非心源性危重病患者有较高的MODS发生率、机械通气使用率和住院病死率,需要更长时间的ICU治疗和更高昂的住院费用,监测cTnI水平在此类患者病情评估和治疗中有重要作用.  相似文献   

5.
老年危重病患者应激性高血糖的强化胰岛素治疗   总被引:5,自引:0,他引:5  
目的探讨早期强化胰岛素治疗老年危重病患者应激性高血糖的临床疗效。方法70例发生应激性高血糖(血糖持续>12mmol/L)的老年(>65岁)危重病患者,APACHEⅡ评分平均为(17.2±3.8)分,随机分为强化胰岛素治疗组与常规胰岛素治疗组各35例。强化组血糖控制在4.4~7.8mmol/L;常规组血糖控制在10.0~12.0mmol/L,两组其余临床治疗相同。监测血清C反应蛋白水平变化、泵入胰岛素天数、入住ICU天数、院内感染发生率、需要血液净化治疗的急性肾衰竭的发生率、病死率等指标。结果强化组老年危重病患者的C反应蛋白水平、泵入胰岛素天数、住ICU天数、院内感染发生率、需要血液净化治疗的急性肾衰竭的发生率、死亡率显著降低,与常规组比较差异有统计学意义(P<0.05或<0.01)。结论对于发生应激性高血糖的老年危重病患者,早期强化胰岛素治疗能更有效、更及时地控制血糖,并显著改善临床疗效。  相似文献   

6.
大黄对危重病患者胃肠功能衰竭的治疗作用   总被引:9,自引:0,他引:9  
目的 研究大黄对危重病患者胃肠功能衰竭的治疗及对多器官功能障碍综合征 (MODS)的防治作用。方法  96例入住ICU胃肠功能衰竭的危重病患者 ,分为两组 :大黄治疗组 ( 5 6例 )和对照组 ( 4 0例 ) ,观察两组患者胃肠功能衰竭的缓解率、缓解时间及MODS的发生率、病死率等。结果 大黄治疗组胃肠功能衰竭的缓解率为 80 .4% ,对照组为 40 .0 % ,两组间有显著性差异 (P <0 .0 1)。大黄治疗后胃肠功能衰竭的持续时间明显缩短。大黄治疗组和对照组MODS的发生率分别为 2 8.6%、62 .5 % ,MODS的病死率分别为 2 5 .0 %、60 .0 % ,两组比较有显著性差异。结论 大黄对危重病患者胃肠功能衰竭具有较好的治疗作用 ,可明显降低MODS的发生率和病死率。  相似文献   

7.
谷氨酰胺在危重病患者中的应用   总被引:3,自引:0,他引:3  
目的探讨危重病患者中早期经静脉应用谷氨酰胺(glutamine,Gl)的临床价值。方法42例患者随机分成两组(对照组和Gln组),Gln组进行Gln治疗(100mL/d,共7d)。治疗前后检测患者体质量、白蛋白、谷胱甘肽(GSH)、握力的变化和肠功能不全的发生率。结果体质量两组治疗前后比较差异无显著性(P〉0.05)。白蛋白、握力和GSH Gl治疗后非常显著高于治疗前(P〈0.01);白蛋白对照组治疗后较治疗前显著增高(P〈0.05),但握力和GSH治疗前后均无显著变化(P〉0.05);肠功能不全的发生率Gln组为4.8%,显著低于对照组(28.6%,P〈0.05)。结论在危重病患者疾病早期通过静脉途径外源性地补充Gln,有效改善了患者的营养状况;使患者血浆中的GSH水平增高,加强了机体的抗氧化能力;减少了患者肠功能不全的发生率。  相似文献   

8.
强化胰岛素治疗在危重病患者中的临床疗效观察   总被引:19,自引:0,他引:19  
目的 研究强化胰岛素治疗在危重病患者中的临床疗效。方法 6 0例危重病患者血糖水平为18 .34±6 73mmol/L ,随机分为治疗组(n =30 )给予强化胰岛素治疗,使血糖控制在4 . 4~6 . 1mmol/L ;对照组(n =30 )给予常规胰岛素治疗,使血糖控制在10 .0~11. 7mmol/L。观察两组患者静滴胰岛素天数、使用抗生素天数、入住ICU天数、出现死亡天数、院内感染发生率、死亡率等反映病情疗效的参数。结果 治疗组中静滴胰岛素天数(10. 0±2 . 8)d、使用抗生素天数(14. 5±3 .4 )d、入住ICU天数(11 .0±4 . 6 )d、出现死亡天数(7 ,5±2 .8)d、院内感染发生率(13, 3% )、死亡率(16. 5 % )均明显低于对照组(P <0 . 0 5 ) ,有显著性差异。结论 对于危重病患者即使无糖尿病,当出现血糖水平持续升高时,强化胰岛素治疗可改善危重病患者的病情,降低死亡率。  相似文献   

9.
刘树峰  虎晓岷 《临床荟萃》2012,27(20):1762-1764
目的探讨血必净注射液对危重病患者可溶性髓系细胞表达的触发受体1(sTREM-1)及炎症因子表达的影响。方法将入住我院重症加强治疗病房(ICU)的危重病患者92例随机分为常规治疗组44例和与血必净治疗组48例,在相同的常规治疗基础上,血必净治疗组给予血必净注射液100ml静脉滴注,每日2次,连续使用7天。两组患者治疗前及治疗后7天,分别抽血检测sTREM-1、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素10(IL-10)的水平,记录全身炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)发生的情况及预后。结果血必净治疗组能明显降低危重病患者体内sTREM-1、TNF-α、IL-6、IL-6/IL-10水平,治疗后sTREM-1和IL-6明显低于常规治疗组(49.17±30.42)ng/L vs(70.24±36.17)ng/L;(20.41±21.72)ng/L vs(54.91±21.02)ng/L(P<0.01),MODS发生率、28天病死率明显下降(P<0.05)。结论血必净注射液能有效改善患者预后,降低脏器功能不全的发生率,其机制可能与降低体内sTREM-1的水平、减轻全身炎症反应有关。  相似文献   

10.
目的探讨改良宣教及探视方法对心脏术后患者ICU谵妄的影响。方法选取2017年11月—2019年10月在本院进行心脏手术后入ICU监护治疗的76例患者为研究对象,其中将2018年11月—2019年10月的39例患者作为观察组,将2017年11月—2018年10月的37例患者作为对照组。观察组采用改良的宣教及探视方法,对照组实施常规宣教及常规探视。将两组患者ICU谵妄及焦虑的发生率、机械通气及入住ICU的时间进行对比。结果观察组患者的谵妄及焦虑的发生率均低于对照组(P0.05),机械通气和入住ICU的时间均明显短于对照组,差异有统计学意义(P0.05)。结论采用改良的宣教及探视方法能有效消除患者的焦虑及紧张情绪,降低ICU谵妄的发生率,缩短患者机械通气时间和入住ICU的时间。  相似文献   

11.
目的探讨谷氨酰胺(Gin)对慢性阻塞性肺疾病患者外周血单个核细胞(PBMC)中热休克蛋白70(HSP70)和肿瘤坏死因-α(TNF-α)表达的影响。方法选择30例COPD急性加重期(AECOPD)患者为研究对象,设为AECOPD组.将治疗10~20d后处于稳定期的上述患者设为SCOPD组,分别以Gin干预,并以健康人为正常对照组。采用Real—timePCR法检测上述5组PBMC中HSP70mRNA和TNF-α mRNA的表达水平。结果AECOPD和SCOPD空白对照组HSP70mRNA、TNF-α mRNA的表达高于正常对照组,差异有统计学意义(t分别=-3.74、-3.57、-3.63、-3.31,P均〈0.05);AECOPD组和SCOPD组中,用Gin干预的较未用Gln的PBMC中HSP70表达均升高,差异有统计学意义(t分别=4.87、2.81,P均〈0.05),而TNF-α表达均下降(t分别=-3.42、-2.97,P均〈0.05)。结论Gin可抑制COPD患者炎症因子TNF-α的活性,升高HSP70的表达。  相似文献   

12.

BACKGROUND:

Glutamine (Gln) supplementation is known to decrease oxidative stress and inflammatory response, enhance resistance to infectious pathogens, shorten hospital stay, and decrease medical costs of patients. This study was undertaken to evaluate the relationship between the effect of early parenteral glutamine (Gln) supplement on acute liver injury (ALI) and heat shock protein 70 (HSP-70) expression in critical patients.

METHODS:

Forty-four patients who had been admitted to the emergency intensive care unit (EICU) of Nanjing First Hospital Affiliated to Nanjing Medical University were randomly divided into a control group (n=22) and a Gln group (n=22). The patients of the two groups received enteral and parenteral nutrition. In addition, parenteral Gln 0.4 g/kg per day was given for 7 days in the Gln group. Serum HSP-70 and Gln were measured at admission and at 7 days after admission. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBiL), serum levels of HSP-70 and Gln, mechanical ventilation (MV) time, ICU stay, peripheral blood of TNF-α, IL-6, CD3, CD4 and CD4/CD8 levels were also measured in the two groups.

RESULTS:

In the Gln group, the levels of serum HSP-70 and Gln were significantly higher after Gln treatment than those before the treatment (P<0.01). HSP-70 level was positively correlated with the Gln level in the Gln group after administration of parenteral Gln (P<0.01). The levels of serum ALT, AST, TBiL and TNF-α, IL-6 were lower in the Gln group than in the non-Gln group (P<0.01). MV time and ICU stay were significantly different between the two groups (P<0.05). The levels of CD3, CD4 and CD4/CD8 were significantly higher in the Gln group than in the control group after treatment (P<0.05).

CONCLUSION:

Parenteral Gln significantly increases the level of serum HSP70 in critically ill patients. The enhanced expression of HSP70 is correlated with improved outcomes of Gln-treated patients with acute liver injury.KEY WORDS: Glutamine, Heat shock protein, Critically ill patients, Acute liver injury  相似文献   

13.
Objective Heat shock protein 70 (HSP-70) is protective against cellular and tissue injury. Increased serum HSP-70 levels are associated with decreased mortality in trauma patients. Glutamine (Gln) administration increases serum and tissue HSP-70 expression in experimental models of sepsis. Gln has been safely administered to critically ill patients and can improve clinical outcomes, but the effect of Gln administration on HSP-70 expression in humans is unknown. We examined whether Gln-supplemented parenteral nutrition (PN) increases serum HSP-70 levels in critically ill patients.Design and setting Randomized, controlled, double-blind study in surgical intensive care units (SICU) in a university hospital.Patients 29 patients admitted to the SICU and requiring PN for more than 7 days.Interventions Patients received either Gln-PN (containing alanyl-glutamine dipeptide; 0.5 g/kg per day; n=15) or standard Gln-free PN (control-PN) that was iso-nitrogenous to Gln-PN (n=14). Serum HSP-70 concentrations were measured at enrollment and at 7 days. Clinical outcome measures were also determined.Results HSP-70 concentrations were unchanged in control-PN subjects from baseline to day 7. In marked contrast, Gln-PN subjects demonstrated significantly higher (3.7-fold) serum HSP-70 concentrations than control subjects. In Gln-PN patients there was a significant correlation between increases in HSP-70 levels over baseline and decrease in ICU length of stay.Conclusions Gln-PN significantly increases serum HSP-70 in critically ill patients. The magnitude of HSP-70 enhancement in Gln-treated patients was correlated with improved clinical outcomes. These data indicate the need for larger, randomized trials of the Gln effect on serum and tissue HSP-70 expression in critical illness and relationship to clinical outcomes.  相似文献   

14.
目的探讨血清热休克蛋白70(HSP70)水平对老年心功能不全的临床价值。方法将100例老年入选者分为正常对照组与心功能不全组,心功能不全组根据临床心功能NYHA分级分为I~Ⅳ级组,测定各组血清HSP70水平、左心室射血分数(LVEF)及左心室舒张末期横径(LVEDd),并作分析与比较。结果心功能不全病人血清HSP70、LVEDd显著高于正常对照组(t=8.55、10.28,P〈0.05),LVEF显著低于正常对照组(t=10.40,P〈0.05)。除I级组与正常对照组间HSPT0水平差异无统计学意义外,其余各组间HSPT0水平差异均有统计学意义(F=115.25,q=3.03~25.92,P〈0.05、0.01)。心功能不全各组间LVEF、LVEDd比较,差异均有统计学意义(F=127.89、75.37,q=4.42-28.66,P〈0.01)。心功能不全病人HSP70水平与LVEF呈负相关(rs=0.832,P〈0.01),与LVEDd呈正相关(r5=0.772,P〈0.01)。结论血清HSP70水平与老年心功能不全心功能分级关系密切,随其严重程度的增加而升高,对老年心功能不全的临床诊断和病情评估具有重要价值。  相似文献   

15.
OBJECTIVE: Glutamine is recognized as a conditionally indispensable amino acid. The purpose of the current study was to investigate whether supplemental l-alanyl-l-glutamine to parenteral nutrition can alter clinical outcome in intensive care unit patients. DESIGN: Prospective, open, randomized trial. SETTING: Postoperative intensive care unit of a university hospital. PATIENTS: Male and female critically ill patients with indications for parenteral nutrition and an expected stay on intensive care unit for >or=5 days. INTERVENTIONS: Patients were randomized to receive either standard parenteral nutrition or supplemented parenteral nutrition with l-alanyl-l-glutamine (0.3 g.kg.body weight [bw] per day). Total amount of amino acids comprised 1.5 g.kg.bw per day. Caloric support was managed by metabolic variables (glucose and triglyceride plasma values). Target values for energy supply were 3 g.kg.bw carbohydrates and 1 g.kg.bw fat per day. MEASUREMENTS AND MAIN RESULTS: Medical treatment, nutritional therapy, vital variables, and biochemical data were recorded. Clinical outcome was measured by average length of stay in the intensive care unit and hospital and the mortality in the intensive care unit and within 30 days and 6 months. A total of 144 patients were randomized; 95 patients were treated for >or=5 days and 68 patients for >or=9 days under standardized conditions. In the treatment group, plasma glutamine concentrations significantly increased within 6-9 days. Six-month survival was significantly improved for patients treated for >or=9 days (66.7% [glutamine supplemented] vs. 40% [control]). CONCLUSION: Study results support the hypothesis that replacement of glutamine deficiency may correct the excess mortality in intensive care unit patients caused by inadequate parenteral nutrition.  相似文献   

16.
肠内和肠外营养对重症急性胰腺炎的治疗作用   总被引:7,自引:1,他引:6  
目的:探讨合理的营养方式对重症急性胰腺炎(SAP)患者治疗的作用。方法:将60例SAP患者随机分为全胃肠外营养支持(对照组)和肠内与肠外相结合营养支持(实验组)两组,分别检测血清前白蛋白、转铁蛋白、CD 4/CD 8比值和血清IgG水平、血清内毒素及尿乳果糖/甘露醇(L/M)比值,以监测两组患者营养状况、肠黏膜通透性和免疫状态的变化。结果:实验组治疗7 d后血清前白蛋白、转铁蛋白均较治疗前明显升高(P均<0.05),且实验组改善程度好于对照组。实验组治疗7 d和15 d血清内毒素及尿L/M值均低于对照组(P均<0.05)。治疗15 d后血清IgG和CD 4/CD 8比值均较7 d时明显升高(P均<0.05),且好于对照组(P均<0.05)。结论:肠内与肠外结合的营养支持方式可以改善SAP患者的营养状况,增强免疫力,维持肠黏膜屏障,对SAP患者治疗有积极的作用。  相似文献   

17.
危重症肠内加肠外营养支持的护理研究   总被引:13,自引:1,他引:12  
目的 探讨肠内加肠外营养支持在危重病患者中的合理应用。方法 对186例收住ICU的危重病患者随机分成肠外营养组(PN)87例,肠内加肠外营养组(EN PN)99例,观察两组不同营养支持方法的效果及并发症发生情况,并对监测结果进行统计学处理。结果单纯PN组并发症高,易发生高血糖及肝功能损害,维持营养状态效果差,最终导致胃肠功能衰竭。而EN PN组并发症少,疗效高,降低了MODS发生率。结论 对危重病人早期实施EN PN营养支持,不仅可有效防治胃肠功能衰竭,同时在降低危重病人的病死率,减少并发症和促进患者康复方面均起到重要作用。  相似文献   

18.
目的 观察缺血预适应(IP)对在体大鼠肺缺血-再灌注(I/R)损伤细胞凋亡及热休克蛋白(HSP70)表达的影响,探讨其作用的可能机制.方法 雄性SD大鼠36只,随机分为3组:假手术(SO)组,缺血.再灌注(I/R)组,缺血预适应(IP)组,每组12只.I/R组开胸后用无创微血管钳钳夹肺门远心端,阻断肺门(观察肺无舒缩为阻断标准),建立在体肺脏L/R损伤模型.IP组于缺血开始前,应用3个循环的5min缺血+5 min灌注进行预处理.假手术组仅予开胸术.各组均于2h、5 h时结扎肺门取出左肺.用原位末端标记法(TUNEL)检测细胞凋亡指数,免疫组化法测定HSPT0表达.计算肺湿干比(W/D),肺泡损伤数定最评价指标(IQA),同时在光镜与电镜下观察肺脏的病理形态学和超微结构的改变.为应用单因素方差分析,组间两两比较采用scheffe检验.结果 与SO组比较,I/R组凋亡指数2 h点为21.37±4.35、5h点为19.67±3.64,均增加(P=0.000),HSP 70表达2 h点为0.187±0.019、5 h点为0.207±0.021均增加(P=0.000),W/D 2 h点为6.65±0.85、5 h点为7.10±0.94,均增加(P=0.000),IQA 2 h点为45.95±2.82、5 h点为55.77±3.24均显著升高(P:0.000).与I/R组比较,IP组凋亡指数2 h点为14.02±3.15(P=0.005)、5 h点为12.18±2.29(P=0.001),均明显下降,HSP70表达2 h点为0.240±0.017(P=0.000)、5 h点为0.260±0.022(P=0.002),均增强,W/D 2 h点为5.39±0.36(P=0.074)、5 h点为5.47±0.44(P=0.003),有不同程度降低、IQA 2 h点为25.77±3.77、5 h点为30.35±3.69,差异具有统计学意义(P=0.000).肺脏超微结构损害和肺水肿程度明显减轻.结论 缺血预适应对肺缺血.再灌注损伤有保护作用,其机制可能是通过上调HSP70的表达而抑制细胞凋亡来实现的.  相似文献   

19.
OBJECTIVE: To determine whether the genotype and allelic frequencies of two human leukocyte antigen-linked bi-allelic 70-kilodalton heat shock protein (HSP70) gene polymorphisms are associated with susceptibility to and outcome of severe sepsis. Furthermore, we investigated a possible linkage between HSP70 gene polymorphisms and the previously reported and mortality-related tumor necrosis factor-beta (TNF-beta) NcoI gene polymorphism. DESIGN: Consecutive entry study of patients with severe sepsis. SETTING: Surgical intensive care unit in a university hospital. PATIENTS: Eighty-seven patients with a diagnosis of severe sepsis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We studied two bi-allelic polymorphisms within the coding region of the constitutively expressed HSP70-HOM C/T, and the stress-inducible HSP70-2 G/A in patients with severe sepsis. The HSP70-HOM Ncol, HSP70-2 Pstl, and TNF-beta NcoI polymorphisms were identified by means of the polymerase chain reaction followed by restriction analysis of the polymerase chain reaction product. No significant differences in genotype and allelic frequencies were observed for both HSP70 gene polymorphisms between the 87 patients and the 110 healthy Caucasians serving as the control group. In addition, no differences in genotype and allelic frequencies between surviving and nonsurviving patients were detected. The allelic frequencies in the group of nonsurvivors were 0.8 for the HSP70-HOM C allele and 0.2 for the HSP70-HOM T allele vs. 0.87 and 0.13 for the survivors (p > .05). The frequency for the HSP70-2 G allele was 0.36 and 0.64 for the HSP70-2 A allele in the group of nonsurvivors vs. 0.41 and 0.59 for the survivors (p > .05). Analysis of a possible linkage between HSP70 and TNF-beta genotypes resulted in a significant association (odds ratio, 4.15; p < .01) of the HSP70-2 A/A homozygous genotype and the TNFB2/B2 homozygous genotype, which is reported to be a genomic marker for a poor prognosis in severe sepsis. CONCLUSIONS: Our data show that the bi-allelic NcoI and PstI polymorphisms within the HSP70-HOM and HSP70-2 locus, respectively, are associated with neither susceptibility to nor outcome of severe sepsis. Moreover, we found a linkage between HSP70-2 A homozygotes and the previously reported and mortality-related homozygous genotype, TNFB2/B2, in patients suffering from severe sepsis.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号